Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
26
SGIOY Quote, Financials, Valuation and Earnings
Last price:
$8.51
Seasonality move
:
1.92%
Day range:
$8.46 - $8.55
52-week range:
$6.71 - $9.23
Dividend yield:
0%
P/E ratio:
12.65x
P/S ratio:
4.94x
P/B ratio:
1.49x
Volume:
190.4K
Avg. volume:
113.8K
1-year change:
18.69%
Market cap:
$14.5B
Revenue:
$2.9B
EPS (TTM):
$0.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SGIOY
Shionogi & Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 2.78% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SGIOY
Shionogi & Co., Ltd.
|
$8.51 | -- | $14.5B | 12.65x | $0.11 | 0% | 4.94x |
|
HLOSF
Healios KK
|
$2.50 | -- | $288.5M | -- | $0.00 | 0% | 392.54x |
|
PPTDF
PeptiDream Inc.
|
$10.95 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.00 | -- | $452.5M | -- | $0.00 | 0% | 2.34x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.18 | $17.76 | $44.8B | 179.95x | $0.32 | 4.66% | 1.53x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SGIOY
Shionogi & Co., Ltd.
|
1.56% | 0.104 | 1.03% | 2.89x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SGIOY
Shionogi & Co., Ltd.
|
$649.3M | $275.7M | 12.16% | 12.33% | 35.92% | $305.2M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Shionogi & Co., Ltd. vs. Competitors
-
Which has Higher Returns SGIOY or HLOSF?
Healios KK has a net margin of 39.04% compared to Shionogi & Co., Ltd.'s net margin of -9751.87%. Shionogi & Co., Ltd.'s return on equity of 12.33% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital SGIOYShionogi & Co., Ltd.84.61% $0.18 $9.9B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About SGIOY or HLOSF?
Shionogi & Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & Co., Ltd. has higher upside potential than Healios KK, analysts believe Shionogi & Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SGIOYShionogi & Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is SGIOY or HLOSF More Risky?
Shionogi & Co., Ltd. has a beta of 0.191, which suggesting that the stock is 80.886% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock SGIOY or HLOSF?
Shionogi & Co., Ltd. has a quarterly dividend of $0.11 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & Co., Ltd. pays 22.37% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Shionogi & Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SGIOY or HLOSF?
Shionogi & Co., Ltd. quarterly revenues are $767.5M, which are larger than Healios KK quarterly revenues of $128.8K. Shionogi & Co., Ltd.'s net income of $299.6M is higher than Healios KK's net income of $3.8M. Notably, Shionogi & Co., Ltd.'s price-to-earnings ratio is 12.65x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & Co., Ltd. is 4.94x versus 392.54x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGIOYShionogi & Co., Ltd.4.94x 12.65x $767.5M $299.6M HLOSFHealios KK392.54x -- $128.8K $3.8M
-
Which has Higher Returns SGIOY or PPTDF?
PeptiDream Inc. has a net margin of 39.04% compared to Shionogi & Co., Ltd.'s net margin of -25.38%. Shionogi & Co., Ltd.'s return on equity of 12.33% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital SGIOYShionogi & Co., Ltd.84.61% $0.18 $9.9B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About SGIOY or PPTDF?
Shionogi & Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Shionogi & Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings SGIOYShionogi & Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is SGIOY or PPTDF More Risky?
Shionogi & Co., Ltd. has a beta of 0.191, which suggesting that the stock is 80.886% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock SGIOY or PPTDF?
Shionogi & Co., Ltd. has a quarterly dividend of $0.11 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & Co., Ltd. pays 22.37% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Shionogi & Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SGIOY or PPTDF?
Shionogi & Co., Ltd. quarterly revenues are $767.5M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Shionogi & Co., Ltd.'s net income of $299.6M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Shionogi & Co., Ltd.'s price-to-earnings ratio is 12.65x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & Co., Ltd. is 4.94x versus 11.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGIOYShionogi & Co., Ltd.4.94x 12.65x $767.5M $299.6M PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns SGIOY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 39.04% compared to Shionogi & Co., Ltd.'s net margin of -24.76%. Shionogi & Co., Ltd.'s return on equity of 12.33% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital SGIOYShionogi & Co., Ltd.84.61% $0.18 $9.9B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About SGIOY or SOLTF?
Shionogi & Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Shionogi & Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SGIOYShionogi & Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is SGIOY or SOLTF More Risky?
Shionogi & Co., Ltd. has a beta of 0.191, which suggesting that the stock is 80.886% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock SGIOY or SOLTF?
Shionogi & Co., Ltd. has a quarterly dividend of $0.11 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & Co., Ltd. pays 22.37% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Shionogi & Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SGIOY or SOLTF?
Shionogi & Co., Ltd. quarterly revenues are $767.5M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Shionogi & Co., Ltd.'s net income of $299.6M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Shionogi & Co., Ltd.'s price-to-earnings ratio is 12.65x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & Co., Ltd. is 4.94x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGIOYShionogi & Co., Ltd.4.94x 12.65x $767.5M $299.6M SOLTFNxera Pharma Co., Ltd.2.34x -- $45.8M -$11.3M
-
Which has Higher Returns SGIOY or STMM?
Stemcell Holdings, Inc. has a net margin of 39.04% compared to Shionogi & Co., Ltd.'s net margin of --. Shionogi & Co., Ltd.'s return on equity of 12.33% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SGIOYShionogi & Co., Ltd.84.61% $0.18 $9.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About SGIOY or STMM?
Shionogi & Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Shionogi & Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SGIOYShionogi & Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is SGIOY or STMM More Risky?
Shionogi & Co., Ltd. has a beta of 0.191, which suggesting that the stock is 80.886% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SGIOY or STMM?
Shionogi & Co., Ltd. has a quarterly dividend of $0.11 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & Co., Ltd. pays 22.37% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Shionogi & Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SGIOY or STMM?
Shionogi & Co., Ltd. quarterly revenues are $767.5M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Shionogi & Co., Ltd.'s net income of $299.6M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Shionogi & Co., Ltd.'s price-to-earnings ratio is 12.65x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & Co., Ltd. is 4.94x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGIOYShionogi & Co., Ltd.4.94x 12.65x $767.5M $299.6M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns SGIOY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 39.04% compared to Shionogi & Co., Ltd.'s net margin of -1.05%. Shionogi & Co., Ltd.'s return on equity of 12.33% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital SGIOYShionogi & Co., Ltd.84.61% $0.18 $9.9B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About SGIOY or TAK?
Shionogi & Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 25.04%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Shionogi & Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Shionogi & Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SGIOYShionogi & Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is SGIOY or TAK More Risky?
Shionogi & Co., Ltd. has a beta of 0.191, which suggesting that the stock is 80.886% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock SGIOY or TAK?
Shionogi & Co., Ltd. has a quarterly dividend of $0.11 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.66% to investors and pays a quarterly dividend of $0.32 per share. Shionogi & Co., Ltd. pays 22.37% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Shionogi & Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios SGIOY or TAK?
Shionogi & Co., Ltd. quarterly revenues are $767.5M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Shionogi & Co., Ltd.'s net income of $299.6M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Shionogi & Co., Ltd.'s price-to-earnings ratio is 12.65x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 179.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & Co., Ltd. is 4.94x versus 1.53x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SGIOYShionogi & Co., Ltd.4.94x 12.65x $767.5M $299.6M TAKTakeda Pharmaceutical Co., Ltd.1.53x 179.95x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
